Day: October 3, 2024

By regulatory requirement,THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ~ AGM to approve re-capitalization ~~ Announces name change ~ RENO, Nev., Oct. 03, 2024 (GLOBE NEWSWIRE) — NuLegacy Gold (the “Company”) reports that on account of the pending October 7th annual and special general meeting (the “AGM”) to authorize a re-capitalization of the Company’s issued common shares it has terminated the Company’s current 100,000,000-unit non-brokered private placement announced on August 15 and 28, 2024 (the “Offering”). In total, the Company issued 45,200,000 units (“Units”) at a price of $0.01 per Unit for gross proceeds of $452,000, of which 40,000,000 Units were purchased by Crescat Portfolio Management LLC (“Crescat”) together with various directors and officers of the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR HONG KONG OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Company Announcement No. 1137 Completion of equity offering and directed issue of new shares raising gross proceeds of DKK 37.3 billion (approx. EUR 5 billion). Today 4 October 2024, the offering (the “Offering”) of 26,444,523 new shares (the “New Shares”) in DSV A/S (“DSV”) has been successfully completed through an accelerated bookbuilding process. The New Shares will be issued as a result of DSV’s Board of Directors exercising the authorisation in Article 4a1 of DSV’s Articles of Association according to which the Board of Directors is authorised to make share capital increases up to nominally...

Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities. “We are pleased to partner with DRI to monetize a portion of the licensing payments from the Vertex Cas9 license deal we announced last December, providing us with considerable...

THE WOODLANDS, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 579 homes in September 2024, a 7.2% year-over-year increase, resulting in a total of 1,757 homes closed during the third quarter of 2024. As of September 30, 2024, the Company had 138 active selling communities. The Company plans to release financial results for the third quarter ended September 30, 2024, before the market opens on Tuesday, November 5, 2024. The Company will hold a conference call at 12:30 p.m. Eastern Time the same day to discuss the results. A link to the live audio webcast will be provided through the Investor Relations page of the Company’s website at www.investor.lgihomes.com under the Events and Presentations section. An archive of the webcast will be available for replay on the Company’s...

MEXICO CITY, Oct. 03, 2024 (GLOBE NEWSWIRE) — Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central, and South America, reports its September 2024 preliminary traffic results. In September 2024, Volaris’ ASM capacity decreased by 12.8% year-over-year due to the accelerated Pratt & Whitney engine inspections and the resulting aircraft groundings. Volaris transported 2.3 million passengers during the month at a load factor of 85.0%, a 1.2 pp increase compared to last year. RPMs for the month decreased by 11.5%, with Mexican domestic RPMs down by 18.5%, while international RPMs increased 2.1%. Enrique Beltranena, Volaris’ President and CEO said: “Volaris finished the third quarter with...

NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus2+ study of its UX701 gene therapy has demonstrated meaningful clinical activity as well as improvements in copper metabolism in Stage 1. Multiple responders have completely tapered off of standard-of-care treatment with responses seen in all three dose cohorts. The company plans to enroll an additional cohort in Stage 1 at a moderately increased dose and with an optimized immunomodulation regimen to enhance the efficiency and efficacy of the gene therapy, with the objective of having the majority of patients come off of standard-of-care treatment before selecting a dose for the randomized placebo-controlled stage of the study. In Stage 1, 15 patients were enrolled into three sequential dosing...

DELAWARE, Ohio, Oct. 03, 2024 (GLOBE NEWSWIRE) — Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced that Vicki Avril-Groves will be retiring from the Greif Board of Directors effective November 1, 2024, due to personal reasons. She joined the Board in 2004 and has served on a variety of Board committees, including the Audit Committee as Chairperson for several years. “On behalf of the entire Board of Directors, I want to thank Vicki for her valuable insight and dedication to Greif over the past 20 years,” said Bruce Edwards, Greif Board Chairman. “Vicki has provided valuable counsel and guidance helping the company grow and evolve into the organization it is today. She will be missed, and we wish her well.” About Grief Greif is a global leader in...

Adam Draizin Steps Down;TILT Veteran Marshall P. Horowitz Joins Board PHOENIX, Oct. 03, 2024 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announced that Adam Draizin has stepped down from the Company’s Board of Directors (the “Board”) effective October 1 and Marshall P. Horowitz was appointed to the Board effective October 2. Mr. Horowitz previously served as the first General Counsel for TILT Holdings. Mr. Horowitz brings decades of global legal and transactional experience to this board position, representing noteholders of TILT Holdings. “We’d like to thank Adam for his time and contributions while serving on the Board,”...

Seasoned Healthcare Executive Brings Robust Financial Strategy Experience, Including Previous Role as Chief Financial Officer and Chief Accounting Officer of AMN for More Than 10 Years DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN) (“AMN” or “the Company”), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced that Brian Scott has been appointed Chief Financial Officer and Chief Operating Officer, effective November 21, 2024. In this role, Mr. Scott will be responsible for AMN’s finance and enterprise operating functions as the Company continues to evolve its model to be more automated and scaled. Mr. Scott is returning to AMN, where he previously held a variety of roles of increasing responsibility in finance, strategy and accounting...

CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been corrected to Tungsten Advisors. The corrected release follows. Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced the signing and closing of a private placement of (i) 3,499 shares of the Company’s Series C Convertible Preferred Stock, $0.00001 par value (the “Series C Preferred Stock”), and (ii) warrants (the “Warrants”) to acquire up to an aggregate of 591,856 additional...